Protalix BioTherapeutics, Inc. (NYSE:PLX)
Industry: Healthcare

OFF LIST - 1361 consecutive market days: OFF LIST as of 01/07/2011 Through 11/14/2016

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials for the treatment of Fabry diseases; OPRX-106, an orally-delivered protein product candidate for the treatment of inflammatory bowel disease, as well as completed Phase IIa clinical trial for ulcerative colitis patients; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; and PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. was founded in 1993 and is headquartered in Karmiel, Israel.

Current Quote*
Last: $2.180
Change: -0.010
Book: $Unk
Volume: 24,631

As Of: 04/03 12:58 ET
*Quotes delayed by 20min.

Graphs for PLX

3 Month Graph

6 Month Graph

1 Year Graph